Mirava
FDA-cleared patient-specific preoperative organ models manufactured via 3D printing for surgical planning and intraoperative guidance.
- CEO / Founder
- Gary Turner
- Stage
- Active
- Latest Round
- Bootstrapped
Technology & Products
Key Products
Patient-specific anatomic organ models (3D-printed); Surgical planning consultation services
Technological Advantage
Inherited FDA clearance and clinical validation from Ricoh 3D for Healthcare operations; independent founder-operator model (Gary Turner) prioritizes surgical relationships over hardware sales, reducing conflict-of-interest and enabling customized offerings per surgical case. This standalone entity structure allows faster regulatory iteration and customer-centric pricing vs. a diversified printer OEM managing anatomic modeling as one product line among many.
Differentiation
Value Proposition
Reduces surgical planning time and risk by enabling surgeons to practice on patient-specific anatomic models before incision; reduces operative time and complication rates in complex cases.
How They Differentiate
FDA-regulated independent operator model with direct clinical relationships; inherited customer base and Ricoh institutional continuity; focus on surgical outcome optimization rather than technology platform sales.
Market & Competition
Target Customers
Surgical centers, hospitals, specialty surgical practices
Industry Verticals
Healthcare; Medical Devices; Surgical Services
Growth & Milestones
Major Milestones
2025: Management buyout from Ricoh; rebranding to Mirava; FDA 510(k) clearance (pre-spinout, under Ricoh 3D for Healthcare)